Latest / GSD Venture Studios Podcasts by Gary Fowler
Rethinking Rare Disease: The Operating Model Revolution in Therapeutics with David Craig
Join David Craig, Co-Founder, President, and CEO of Sarcomatrix Therapeutics, for a masterclass on disrupting the traditional pharmaceutical development playbook. Rare neuromuscular diseases have long been underserved—not due to a lack of scientific potential, but because legacy pharma cost structures fail to scale to small patient populations. Drawing on 30 years of drug development leadership at industry giants like Amgen, Gilead, and Portola, David shares how Sarcomatrix is testing a lean, hyper-disciplined operating model to translate university research into clinical-grade therapeutics…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.